Neuropace INC Schedule 13G passive stakes

OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC collectively report a 4.4% ownership in NeuroPace, Inc. common stock as of June 30, 2026.

OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC have filed an amendment reporting a 6.2% beneficial ownership stake in NeuroPace Inc.

Soleus Capital Management and affiliated entities report an aggregate beneficial ownership of 8.9% in NeuroPace, Inc. common stock.

KCK LTD. has reported a complete divestment of its common stock holdings in NeuroPace Inc., reducing its beneficial ownership to zero percent.

OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC have jointly reported an 8% beneficial ownership stake in NeuroPace Inc.'s common stock.

Soleus Capital Management and its affiliates have filed an Amendment No. 5 to their Schedule 13G, reporting a combined beneficial ownership of 7.0% in NeuroPace, Inc. common stock.

OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC have filed an Amendment No. 5 to their Schedule 13G, confirming their continued beneficial ownership of 10.5% of NeuroPace Inc.'s common stock as of March 31, 2025.

Polar Capital Holdings Plc and Polar Capital LLP have jointly disclosed a beneficial ownership of 9.13% in NeuroPace Inc., holding 2,972,003 shares of common stock.

Kent Lake PR LLC, Kent Lake Partners LP, and Benjamin Natter have jointly disclosed a beneficial ownership of 4.9% in NeuroPace Inc's common stock as of December 31, 2024.

KCK Ltd. has filed an amended Schedule 13G, revealing a 17.7% beneficial ownership stake in NeuroPace Inc.'s common stock as of December 31, 2024.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed a combined beneficial ownership of 8.3% of NeuroPace Inc.'s common stock as of December 31, 2024.